Brittany Louise Bychkovsky, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
BRCA2 Protein | 3 | 2023 | 797 | 1.220 |
Why?
|
Breast Neoplasms | 21 | 2024 | 20988 | 1.160 |
Why?
|
BRCA1 Protein | 3 | 2023 | 1149 | 1.090 |
Why?
|
Germ-Line Mutation | 8 | 2024 | 1852 | 0.980 |
Why?
|
Genetic Predisposition to Disease | 7 | 2024 | 17878 | 0.710 |
Why?
|
Neoplasms, Second Primary | 2 | 2019 | 1051 | 0.670 |
Why?
|
Tamoxifen | 2 | 2024 | 965 | 0.620 |
Why?
|
Neoplasms, Multiple Primary | 1 | 2021 | 592 | 0.580 |
Why?
|
Endometrial Neoplasms | 2 | 2024 | 1365 | 0.570 |
Why?
|
Carcinoma, Intraductal, Noninfiltrating | 1 | 2024 | 926 | 0.560 |
Why?
|
Genetic Testing | 3 | 2024 | 3533 | 0.530 |
Why?
|
Genes, BRCA2 | 4 | 2024 | 590 | 0.480 |
Why?
|
Neoplasms | 8 | 2022 | 22131 | 0.450 |
Why?
|
Chemotherapy, Adjuvant | 3 | 2016 | 3514 | 0.400 |
Why?
|
Cervix Uteri | 1 | 2015 | 570 | 0.390 |
Why?
|
Receptors, Progesterone | 1 | 2016 | 1129 | 0.390 |
Why?
|
Receptors, Estrogen | 2 | 2016 | 2208 | 0.380 |
Why?
|
Neoadjuvant Therapy | 2 | 2024 | 2827 | 0.360 |
Why?
|
Genotype | 1 | 2024 | 12978 | 0.340 |
Why?
|
Papillomavirus Vaccines | 1 | 2015 | 496 | 0.330 |
Why?
|
Early Detection of Cancer | 6 | 2023 | 3196 | 0.320 |
Why?
|
DNA, Viral | 1 | 2015 | 2195 | 0.320 |
Why?
|
Antineoplastic Agents, Hormonal | 1 | 2016 | 1520 | 0.290 |
Why?
|
Genes, BRCA1 | 2 | 2024 | 753 | 0.280 |
Why?
|
Li-Fraumeni Syndrome | 2 | 2024 | 117 | 0.270 |
Why?
|
Medical Oncology | 2 | 2021 | 2317 | 0.270 |
Why?
|
Ovarian Neoplasms | 1 | 2023 | 4849 | 0.260 |
Why?
|
Population Surveillance | 1 | 2016 | 2595 | 0.260 |
Why?
|
Papillomavirus Infections | 1 | 2015 | 1611 | 0.220 |
Why?
|
Uterine Cervical Neoplasms | 1 | 2015 | 2020 | 0.220 |
Why?
|
Colorectal Neoplasms | 2 | 2022 | 6925 | 0.210 |
Why?
|
Latin America | 4 | 2021 | 407 | 0.210 |
Why?
|
Female | 30 | 2024 | 392148 | 0.210 |
Why?
|
Receptor, erbB-2 | 3 | 2024 | 2553 | 0.200 |
Why?
|
Neoplasm Recurrence, Local | 2 | 2020 | 9277 | 0.200 |
Why?
|
Humans | 37 | 2024 | 760617 | 0.170 |
Why?
|
Blister | 1 | 2010 | 86 | 0.170 |
Why?
|
Chemoprevention | 1 | 2022 | 325 | 0.170 |
Why?
|
Germ Cells | 1 | 2023 | 634 | 0.170 |
Why?
|
Pyoderma Gangrenosum | 1 | 2010 | 84 | 0.160 |
Why?
|
Breast Neoplasms, Male | 1 | 2020 | 212 | 0.160 |
Why?
|
Genetic Counseling | 1 | 2022 | 627 | 0.150 |
Why?
|
Aromatase Inhibitors | 1 | 2022 | 513 | 0.150 |
Why?
|
Tumor Suppressor Protein p53 | 2 | 2024 | 2917 | 0.140 |
Why?
|
Diphosphonates | 1 | 2011 | 635 | 0.140 |
Why?
|
Genes, erbB-2 | 1 | 2016 | 162 | 0.130 |
Why?
|
Neoplasm Staging | 4 | 2024 | 11116 | 0.130 |
Why?
|
Acetic Acid | 1 | 2015 | 60 | 0.130 |
Why?
|
Malawi | 1 | 2017 | 302 | 0.130 |
Why?
|
Neoplasm Metastasis | 2 | 2016 | 4910 | 0.130 |
Why?
|
Biological Therapy | 1 | 2016 | 139 | 0.120 |
Why?
|
Mammography | 4 | 2023 | 2430 | 0.120 |
Why?
|
Medical History Taking | 1 | 2019 | 773 | 0.120 |
Why?
|
Indicators and Reagents | 1 | 2015 | 460 | 0.120 |
Why?
|
Lipopolysaccharides | 1 | 2022 | 2202 | 0.120 |
Why?
|
Ultrasonography, Mammary | 1 | 2016 | 239 | 0.120 |
Why?
|
Antineoplastic Agents | 2 | 2016 | 13635 | 0.120 |
Why?
|
Bone Density Conservation Agents | 1 | 2011 | 794 | 0.120 |
Why?
|
PTEN Phosphohydrolase | 1 | 2020 | 1113 | 0.110 |
Why?
|
Selenoproteins | 1 | 2005 | 215 | 0.110 |
Why?
|
Vaginal Smears | 1 | 2015 | 499 | 0.100 |
Why?
|
Selenium | 1 | 2005 | 417 | 0.100 |
Why?
|
Osteoporosis | 1 | 2011 | 1604 | 0.100 |
Why?
|
Health Planning | 1 | 2013 | 230 | 0.100 |
Why?
|
Alleles | 1 | 2022 | 6861 | 0.090 |
Why?
|
Middle Aged | 12 | 2024 | 220584 | 0.090 |
Why?
|
Positron-Emission Tomography | 2 | 2016 | 6483 | 0.090 |
Why?
|
Papillomaviridae | 1 | 2015 | 1117 | 0.080 |
Why?
|
National Health Programs | 1 | 2013 | 440 | 0.080 |
Why?
|
Bone Neoplasms | 1 | 2011 | 2527 | 0.080 |
Why?
|
Aged | 12 | 2024 | 169042 | 0.080 |
Why?
|
Referral and Consultation | 2 | 2023 | 3599 | 0.080 |
Why?
|
Caribbean Region | 2 | 2021 | 192 | 0.080 |
Why?
|
Ambulatory Care | 1 | 2019 | 2768 | 0.070 |
Why?
|
Retrospective Studies | 4 | 2024 | 80566 | 0.070 |
Why?
|
Adult | 10 | 2024 | 220969 | 0.070 |
Why?
|
Male | 7 | 2022 | 360358 | 0.070 |
Why?
|
Risk | 1 | 2019 | 9604 | 0.070 |
Why?
|
Incidence | 3 | 2024 | 21337 | 0.070 |
Why?
|
Patient Preference | 1 | 2014 | 925 | 0.070 |
Why?
|
Mannich Bases | 1 | 2005 | 2 | 0.070 |
Why?
|
NADH, NADPH Oxidoreductases | 1 | 2005 | 94 | 0.060 |
Why?
|
Antiprotozoal Agents | 1 | 2005 | 94 | 0.060 |
Why?
|
Antibodies, Monoclonal | 1 | 2011 | 9172 | 0.060 |
Why?
|
Phenotype | 1 | 2022 | 16571 | 0.060 |
Why?
|
Ketones | 1 | 2005 | 183 | 0.060 |
Why?
|
Prevalence | 1 | 2021 | 15689 | 0.060 |
Why?
|
Models, Statistical | 1 | 2019 | 5073 | 0.060 |
Why?
|
Immunotherapy | 1 | 2020 | 4642 | 0.060 |
Why?
|
Randomized Controlled Trials as Topic | 2 | 2016 | 10199 | 0.060 |
Why?
|
Delivery of Health Care, Integrated | 1 | 2012 | 940 | 0.060 |
Why?
|
Follow-Up Studies | 3 | 2020 | 39063 | 0.050 |
Why?
|
Hospitals | 1 | 2017 | 3877 | 0.050 |
Why?
|
Young Adult | 5 | 2024 | 59179 | 0.050 |
Why?
|
Insurance, Health | 1 | 2015 | 2495 | 0.050 |
Why?
|
Cohort Studies | 3 | 2024 | 41457 | 0.050 |
Why?
|
Imaging, Three-Dimensional | 1 | 2016 | 4058 | 0.050 |
Why?
|
Health Services Accessibility | 3 | 2021 | 5430 | 0.050 |
Why?
|
Delivery of Health Care | 2 | 2021 | 5332 | 0.050 |
Why?
|
Mutation | 3 | 2024 | 30016 | 0.050 |
Why?
|
Logistic Models | 1 | 2016 | 13245 | 0.050 |
Why?
|
Mastectomy | 2 | 2024 | 1817 | 0.050 |
Why?
|
Lactation | 1 | 2023 | 397 | 0.050 |
Why?
|
Phthalazines | 1 | 2023 | 383 | 0.040 |
Why?
|
Decision Making | 1 | 2014 | 3918 | 0.040 |
Why?
|
Patient Acceptance of Health Care | 1 | 2014 | 3194 | 0.040 |
Why?
|
Aged, 80 and over | 4 | 2020 | 58894 | 0.040 |
Why?
|
Healthcare Disparities | 2 | 2014 | 3351 | 0.040 |
Why?
|
Heroin Dependence | 1 | 2010 | 172 | 0.040 |
Why?
|
Practice Guidelines as Topic | 1 | 2016 | 7389 | 0.040 |
Why?
|
Prospective Studies | 2 | 2024 | 54360 | 0.040 |
Why?
|
Risk Factors | 2 | 2023 | 74115 | 0.040 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 2011 | 857 | 0.040 |
Why?
|
Heterozygote | 1 | 2024 | 2780 | 0.040 |
Why?
|
Cocaine-Related Disorders | 1 | 2010 | 461 | 0.030 |
Why?
|
Genomics | 2 | 2023 | 5822 | 0.030 |
Why?
|
Breast Feeding | 1 | 2023 | 1354 | 0.030 |
Why?
|
United States | 2 | 2023 | 72272 | 0.030 |
Why?
|
Breast | 1 | 2023 | 1963 | 0.030 |
Why?
|
Medicine, Chinese Traditional | 1 | 2014 | 73 | 0.030 |
Why?
|
West Indies | 1 | 2013 | 32 | 0.030 |
Why?
|
Economic Development | 1 | 2014 | 69 | 0.030 |
Why?
|
Russia | 1 | 2014 | 382 | 0.030 |
Why?
|
Urban Health Services | 1 | 2014 | 176 | 0.030 |
Why?
|
Tomography, X-Ray Computed | 1 | 2016 | 20556 | 0.030 |
Why?
|
Environmental Pollution | 1 | 2014 | 124 | 0.030 |
Why?
|
Cultural Characteristics | 1 | 2014 | 250 | 0.030 |
Why?
|
Developed Countries | 1 | 2015 | 450 | 0.030 |
Why?
|
Cost of Illness | 1 | 2021 | 1935 | 0.020 |
Why?
|
Rural Health Services | 1 | 2014 | 384 | 0.020 |
Why?
|
Kaplan-Meier Estimate | 1 | 2020 | 6474 | 0.020 |
Why?
|
Risk Assessment | 2 | 2023 | 23972 | 0.020 |
Why?
|
Models, Organizational | 1 | 2013 | 544 | 0.020 |
Why?
|
Prognosis | 2 | 2020 | 29600 | 0.020 |
Why?
|
Health Services | 1 | 2014 | 751 | 0.020 |
Why?
|
Biopsy | 1 | 2010 | 6762 | 0.020 |
Why?
|
Brazil | 1 | 2012 | 1228 | 0.020 |
Why?
|
China | 1 | 2014 | 2374 | 0.020 |
Why?
|
Social Stigma | 1 | 2014 | 769 | 0.020 |
Why?
|
India | 1 | 2014 | 2286 | 0.020 |
Why?
|
Trypanosoma brucei rhodesiense | 1 | 2005 | 13 | 0.020 |
Why?
|
Glutathione Reductase | 1 | 2005 | 25 | 0.020 |
Why?
|
Drug Storage | 1 | 2005 | 52 | 0.020 |
Why?
|
Thioredoxin-Disulfide Reductase | 1 | 2005 | 52 | 0.020 |
Why?
|
Trypanocidal Agents | 1 | 2005 | 41 | 0.020 |
Why?
|
Survival Rate | 1 | 2020 | 12719 | 0.020 |
Why?
|
Leishmania donovani | 1 | 2005 | 68 | 0.020 |
Why?
|
Medicare | 1 | 2023 | 6765 | 0.020 |
Why?
|
Radiotherapy | 1 | 2012 | 1497 | 0.020 |
Why?
|
Diagnosis, Differential | 1 | 2010 | 12966 | 0.010 |
Why?
|
Dimethyl Sulfoxide | 1 | 2005 | 251 | 0.010 |
Why?
|
Spectrometry, Mass, Electrospray Ionization | 1 | 2005 | 265 | 0.010 |
Why?
|
Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2005 | 506 | 0.010 |
Why?
|
Health Care Reform | 1 | 2013 | 1247 | 0.010 |
Why?
|
Trypanosoma cruzi | 1 | 2005 | 206 | 0.010 |
Why?
|
Alcoholism | 1 | 2014 | 1972 | 0.010 |
Why?
|
Glutathione | 1 | 2005 | 582 | 0.010 |
Why?
|
Residence Characteristics | 1 | 2012 | 2090 | 0.010 |
Why?
|
Chromatography, High Pressure Liquid | 1 | 2005 | 1540 | 0.010 |
Why?
|
Pregnancy | 1 | 2023 | 29868 | 0.010 |
Why?
|
Adolescent | 2 | 2020 | 88234 | 0.010 |
Why?
|
Treatment Outcome | 2 | 2012 | 64568 | 0.010 |
Why?
|
Antimalarials | 1 | 2005 | 907 | 0.010 |
Why?
|
Socioeconomic Factors | 1 | 2012 | 7798 | 0.010 |
Why?
|
Quality Improvement | 1 | 2013 | 3797 | 0.010 |
Why?
|
Smoking | 1 | 2014 | 9050 | 0.010 |
Why?
|
Mass Screening | 1 | 2012 | 5424 | 0.010 |
Why?
|
Plasmodium falciparum | 1 | 2005 | 1740 | 0.010 |
Why?
|
Predictive Value of Tests | 1 | 2012 | 15251 | 0.010 |
Why?
|
Magnetic Resonance Spectroscopy | 1 | 2005 | 3769 | 0.010 |
Why?
|
Animals | 2 | 2005 | 168201 | 0.010 |
Why?
|